Key result
DOAC initiation for VTE linked to ~47% fewer inpatient visits and lower costs versus LMWH.
Why the study?
Observational studies are limited regarding which first-line drug for venous thromboembolism is associated with lower healthcare resource utilization and cost.
Does DOAC reduce healthcare resource utilization and costs in commercially insured adults with venous thromboembolism compared to LMWH?
Cohort
Does DOAC reduce healthcare resource utilization and costs in commercially insured adults with venous thromboembolism compared to LMWH?
In commercially insured adults with VTE, initiating DOACs is associated with significantly lower healthcare resource utilization and costs compared to LMWH.
Answers are grounded in this paper and cite their sources.
May inform DOAC preference to curb VTE-related utilization in insured adults; leaves open causal confirmation in RCTs.
BACKGROUND: Venous thromboembolism (VTE) can lead to significant healthcare resource utilization (HcRU) and costs. First-line treatments such as direct-acting oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) are utilized for VTE management. There are limited observational studies to determine which first-line drug for VTE is associated with lower HcRU and cost. Therefore, we sought to compare HcRU and costs of commercially insured patients with VTE who initiated DOAC or LMWH in the US. METHODS: We utilized Merative MarketScan Research Database (2016-2021) to identify adults initiating DOAC or LMWH for VTE. Baseline measures were assessed 12 months prior to the index date of drug initiation. Inverse probability of treatment weighting was used to control confounding. For HcRU, logistic regression was used to model emergency room and inpatient visits and the negative binomial count model was used for outpatient visits. The average marginal effect for total healthcare cost comparing DOAC with LMWH users was estimated using a generalized linear model. HcRU and costs were evaluated for 12 months posttreatment initiation. RESULTS: DOAC users had lower odds of inpatient visits (adjusted odds ratio [aOR] 0.53, 95% CI 0.46 to 0.59), emergency room visits (aOR 0.86, 95% CI 0.73 to 0.99), and outpatient visits (adjusted incident rate ratio 0.52, 95% CI 0.50 to 0.54) in comparison to LMWH users. DOAC users had lower total healthcare costs of -$9573 (95% CI -$11,149 to -$7997) (US dollars). CONCLUSION: This cohort study suggests that DOAC use is associated with fewer inpatient, outpatient, and emergency room visits, and lower healthcare costs compared to LMWH use for VTE management.
No takes yet. Share an insight, caveat, or question.
Okoye et al. (2025) conducted a cohort in Venous thromboembolism (VTE). Direct-acting oral anticoagulants (DOAC) vs. Low molecular weight heparins (LMWH) was evaluated on Inpatient visits (aOR 0.53, 95% CI 0.46 to 0.59). DOAC initiation for VTE was associated with lower odds of inpatient visits and lower total healthcare costs (-$9573) compared to LMWH.
Synapse has enriched 10 related papers. Consider them for comparative context: